O astrocitoma anaplásico é um tipo raro de tumor cerebral, grave e agressivo, que nasce das células gliais. Quando visto no microscópio, é caracterizado pela presença de muitos astrócitos com formatos e tamanhos variados, e muitas células se dividindo rapidamente. Geralmente, o tumor se espalha para o tecido cerebral vizinho, causa inchaço significativo, pressiona outras partes do cérebro e pode atingir o lado oposto do cérebro. Dependendo de onde o tumor está localizado, os pacientes podem apresentar sinais de aumento da pressão dentro do crânio (como dor de cabeça, vômitos e inchaço no nervo óptico, conhecido como papiledema), convulsões, perda progressiva de funções neurológicas e/ou alterações no comportamento. O tumor é mais frequentemente encontrado nos lobos frontal e temporal (partes da frente e laterais do cérebro), no tronco cerebral e na medula espinhal.
Introdução
O que você precisa saber de cara
O astrocitoma anaplásico é um tumor cerebral raro e agressivo originado nas células gliais, diagnosticado comumente em adultos. Os pacientes podem sentir fortes dores de cabeça, vômitos, inchaço no nervo dos olhos e convulsões, além de perda gradual de funções neurológicas e mudanças de comportamento. No Brasil, o tratamento é ofertado na rede do SUS conforme a autonomia de cada serviço credenciado, conforme a diretriz de Tumor Cerebral no Adulto. Existem opções com registro sanitário na ANVISA, e a ciência conta com ensaios clínicos em andamento, inclusive com participação brasileira.
O astrocitoma anaplásico é um tipo raro de tumor cerebral, grave e agressivo, que nasce das células gliais. Quando visto no microscópio, é caracterizado pela presença de muitos astrócitos com formatos e tamanhos variados, e muitas células se dividindo rapidamente. Geralmente, o tumor se espalha para o tecido cerebral vizinho, causa inchaço significativo, pressiona outras partes do cérebro e pode atingir o lado oposto do cérebro. Dependendo de onde o tumor está localizado, os pacientes podem apresentar sinais de aumento da pressão dentro do crânio (como dor de cabeça, vômitos e inchaço no nervo óptico, conhecido como papiledema), convulsões, perda progressiva de funções neurológicas e/ou alterações no comportamento. O tumor é mais frequentemente encontrado nos lobos frontal e temporal (partes da frente e laterais do cérebro), no tronco cerebral e na medula espinhal.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.
D-2-hydroxyglutaric aciduria 2
A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.
Medicamentos aprovados (FDA)
1 medicamento encontrado nos registros da FDA americana.
Variantes genéticas (ClinVar)
82 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
4 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Astrocitoma anaplásico
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 10 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
14 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
171 ensaios clínicos encontrados, 26 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 650
Pediatric High-Grade Astrocytoma With Piloid Features: A Comprehensive Literature Review.
High-grade astrocytoma with piloid features (HGAP) is a recently defined central nervous system (CNS) tumor, first introduced into the 2021 World Health Organization (WHO) classification. While predominantly observed in adults, pediatric cases remain rare and poorly characterized. This study aimed to review the epidemiology, clinical features, and molecular profile of pediatric HGAP. A comprehensive review of studies published from 2018 to 2025 was performed to identify methylation-confirmed HGAP cases in patients aged 18 years or younger. Data extracted from studies included subject demographics, tumor location, histological features, molecular alterations, and the implemented treatment sequence. The search identified 17 pediatric cases meeting the inclusion criteria. The median age at diagnosis was 15 years (range: 4-18 years), and a male predilection of approximately twofold was observed. Tumors most commonly arose in the posterior fossa (56.3%). Recurrent molecular alterations included CDKN2A/B loss (75%), FGFR1 mutations or fusions (55.6%), and ATRX loss (45.5%). This review did not identify definitive clinical or histomolecular differences between pediatric and adult HGAP, underscoring the need for further comparative studies. Pediatric HGAP may represent an underrecognized diagnostic entity within the glioma spectrum, emphasizing the critical role of methylation profiling for accurate diagnosis and classification. Retrospective reclassification of histologically and molecularly ambiguous gliomas is warranted and may reveal additional cases. Larger pediatric cohorts are urgently needed to inform clinical management and refine prognostic stratification.
Staining the Invisible: Immunohistochemistry for Early Detection of Mismatch Repair Deficiency in Pediatric High-Grade Brain Tumors.
Constitutional mismatch repair deficiency (CMMRD) is a rare autosomal recessive cancer predisposition syndrome, affecting primarily individuals from consanguineous families, leading to multiple childhood cancers, particularly high-grade central nervous system (CNS) tumors. We retrospectively analyzed 21 pediatric brain tumor samples for mismatch repair (MMR) protein expression via immunohistochemistry (IHC). One patient (4.7%) with anaplastic astrocytoma showed loss of MSH6. CMMRD was confirmed in this case via genetic testing in a sibling. IHC is a practical, low-cost screening tool, especially in resource-limited settings. Routine IHC for MMR proteins in pediatric high-grade CNS tumors may facilitate early CMMRD detection, optimize treatment, and support genetic counseling.
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
The CATNON trial investigated the benefit of the addition of concurrent or adjuvant temozolomide to radiotherapy in individuals with anaplastic astrocytoma. We report the long-term follow-up of the study focusing on the individuals with isocitrate dehydrogenase (IDH) mutated (IDHmt) tumours. This randomised, open-label, phase 3 study in 137 institutions across Australia, Europe, and North America included participants aged 18 years or older with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas and a WHO performance status of 0-2. Participants were randomly assigned (1:1:1:1) centrally using a minimisation technique to radiotherapy alone (59·4 Gy in 33 fractions), radiotherapy with concurrent oral temozolomide (75 mg/m2 per day), radiotherapy with adjuvant oral temozolomide (12 4-week cycles of 150-200 mg/m2 temozolomide given on days 1-5), or radiotherapy with both concurrent and adjuvant temozolomide. Participants were stratified by institution, WHO performance status score, age, 1p loss of heterozygosity, the presence of oligodendroglial elements on microscopy, and MGMT promoter methylation status. The primary endpoint was overall survival adjusted by stratification factors at randomisation in the intention-to-treat population. The eighth amendment of the study protocol (June 27, 2011) incorporated analysis of IDH mutational status into the study. We report the intention-to-treat analysis and the exploratory analysis within the population of participants with astrocytoma with an IDH mutation. As the safety data have been published previously, no safety data are reported. This trial is registered with ClinicalTrials.gov, NCT00626990, and is completed. Between Dec 4, 2007, and Sept 11, 2015, 1407 participants were registered and 751 participants were randomly allocated, 444 of whom were diagnosed with an IDHmt tumour. After a median follow-up for overall survival of 10·9 years (IQR 9·5-12·7), in the intention-to-treat population, adjuvant temozolomide improved overall survival compared with no adjuvant temozolomide (hazard ratio [HR] 0·65 [95% CI 0·54-0·77]), but concurrent did not compared with no concurrent temozolomide (HR 0·91 [0·76-1·08]). In univariable analysis of the participants with an IDHmt tumour, concurrent temozolomide had no statistically significant effect on overall survival (median 9·7 years [8·2-12·5] vs 7·2 years [6·2-9·4]; HR 0·81 [0·63-1·04]), but median overall survival was 12·5 years (95% CI 9·4-15·0) with adjuvant temozolomide compared with 6·0 years (5·1-7·2) with no adjuvant temozolomide (HR 0·54 [0·42-0·69]). No benefit of temozolomide, neither concurrent nor adjuvant, was observed in participants with IDH wild-type tumours. Methylation-based subtyping and several DNA alterations (eg, amplification of PDGFRA and CDK4, homozygous deletion of CDKN2A, and total copy number variation) were associated with worse outcome, none of which was predictive for benefit to temozolomide. Long-term follow-up confirms that radiotherapy followed by 12 cycles of adjuvant temozolomide without concurrent temozolomide during radiotherapy improves survival for individuals with aggressive IDHmt astrocytoma. MSD.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
STELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase (IDH) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m2 once every 6 weeks). The primary end point was overall survival (OS). Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH-mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH-mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
Multifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
Multifocal anaplastic astrocytoma (MAA) is exceedingly rare. The atypical clinical symptoms and imaging characteristics pose significant challenges for accurate clinical diagnosis. A 64-year-old woman presented with clinical symptoms persisting for 3 months, characterized by left-sided facial numbness, an unsteady gait that was lateralized, progressive worsening of incomplete closure of the left eye, dysphagia, and episodes of choking. Based on her clinical symptoms and magnetic resonance imaging (MRI), she was misdiagnosed as primary central nervous system lymphoma. Three months later, her clinical symptoms worsened, and she was admitted to neurosurgery where she underwent a stereotactic biopsy of the left cerebellar hemisphere. Histopathological examination and immunohistochemical analysis were consistent with anaplastic astrocytoma, IDH wild-type status, classified as World Health Organization grade 3. MAA exhibits a rapid progression and is associated with a poor prognosis. Clinicians must enhance their understanding of the MRI manifestations of MAA. Moreover, when MRI findings are insufficient to establish a definitive diagnosis, brain stereotactic examination becomes essential.
Publicações recentes
Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression.
Pediatric High-Grade Astrocytoma With Piloid Features: A Comprehensive Literature Review.
Behavioral Changes and Refractory Hypertension as the First Manifestations of Anaplastic Astrocytoma: A Case Report.
Multifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
A congenital infant-type hemispheric glioma case with EML4::ALK fusion.
📚 EuropePMC346 artigos no totalmostrando 197
Pediatric High-Grade Astrocytoma With Piloid Features: A Comprehensive Literature Review.
Pediatric blood & cancerBehavioral Changes and Refractory Hypertension as the First Manifestations of Anaplastic Astrocytoma: A Case Report.
CureusMultifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
MedicineA congenital infant-type hemispheric glioma case with EML4::ALK fusion.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryDabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.
Neuro-oncology practiceStaining the Invisible: Immunohistochemistry for Early Detection of Mismatch Repair Deficiency in Pediatric High-Grade Brain Tumors.
Pediatric blood & cancerConcurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
The Lancet. OncologySTELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyDesigning a web-based platform for dynamic estimation of individualized conditional survival in grade 3 gliomas.
Discover oncologyGliadel use in a pregnant patient with malignant glioma: a case report.
Frontiers in oncologyEpidemiological characteristics and prognostic factors of high-grade brainstem glioma for all ages and the establishment of a nomogram.
Translational cancer researchAnticancer properties of new flavonoid lensoside Aβ in combination with temozolomide in an in vitro model of human glioma cells.
Brain researchLow-Dose Fractionated Radiation Therapy as a Chemopotentiator of Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma: A Single-Arm Phase 1/2 Trial.
International journal of radiation oncology, biology, physicsSevere Chemoradiotherapy Toxicity in a Pediatric Patient with Leigh Syndrome and Grade IV Isocitrate Dehydrogenase-Mutant Astrocytoma: A Case Report.
The American journal of case reportsThe effect of oncolytic virotherapy on pediatric brain tumor- a systematic review.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryRevisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.
Neuro-oncology advancesSafety assessment of temozolomidee: real-world adverse event analysis from the FAERS database.
Frontiers in pharmacologyIn silico analysis reveals distinct changes in markers of epithelial to mesenchymal transition in glioma subtypes.
Biomolecules & biomedicineIntegrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth.
bioRxiv : the preprint server for biologyRisk of brain and other central nervous system tumors in Danish agricultural workers.
International archives of occupational and environmental healthDrug adverse events associated with temozolomide administration: A real-world pharmacovigilance study using the FAERS database from 2014 to 2024.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersShared decision-making interventions in neuro-oncology practice: a systematic review.
Journal of neuro-oncologyPersistent symmetrical white matter hyperintensities: a case report.
Journal of medical case reportsCell-Specific Vulnerability of Human Glioblastoma and Astrocytoma Cells to Mephedrone-An In Vitro Study.
Molecules (Basel, Switzerland)Nephrogenic Diabetes Insipidus Associated with Temozolomide Therapy in a Patient with Grade IV Astrocytoma.
European journal of case reports in internal medicineSurgical outcomes in high-grade adult type diffuse gliomas (ATDG) with a previous diagnosis of anaplastic astrocytoma without adjuvant therapy.
Clinical neurology and neurosurgeryNovel strategy to target glioblastoma-initiating cells using a braintropic adeno-associated virus carrying a miR-dependent genome-editing system.
British journal of cancerImpact of IDH mutation and adjuvant chemo(radio)therapy on survival outcome in grade II/III astrocytoma: a retrospective cohort study based on SEER database.
Annals of medicine and surgery (2012)Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.
International journal of radiation oncology, biology, physicsPhase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas.
Neuro-oncology advancesRadiosensitizing properties of dual-functionalized carbon nanostructures loaded with temozolomide.
Beilstein journal of nanotechnologyIntegrating nutritional status and hematological biomarkers for enhanced prognosis prediction in glioma patients: A systematic review.
Clinical nutrition ESPENFrequency and Impact of Constitutional Mismatch Repair Deficiency in Patients With High-Grade Glioma, a Retrospective Analysis of 7 Years in Pakistan: an IRRDC Study.
JCO global oncologyA phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.
Journal of neuro-oncologyFree-hand Frameless Pinless Electromagnetic-Navigation (AXIEM™)-Guided Brain Lesion Biopsies: An Institution Based Experience from a Low-Middle-Income Country.
Pakistan journal of medical sciencesQ-Ball high-resolution fiber tractography: Optimizing corticospinal tract delineation near gliomas and its role in the prediction of postoperative motor deficits- A proof of concept study.
Brain & spineStereotactic Photodynamic Therapy of Recurrent Malignant Gliomas.
Sovremennye tekhnologii v meditsineThe engagement of Ras/Raf/MEK/ERK and PLCγ1/PKC pathways regulated by TrkB receptor in resistance of glioma cells to elimination upon apoptosis induction.
NeuropharmacologyHigh-grade astrocytoma with piloid features in the conus medullaris: a rare presentation of a new World Health Organization diagnosis. Illustrative case.
Journal of neurosurgery. Case lessonsEpidemiology and survival of primary intracranial malignant tumor patients with drop metastasis: a population-based analysis.
Acta neurochirurgicaProapoptotic and antimigration properties of osthole in combination with LY294002 against human glioma cells.
Naunyn-Schmiedeberg's archives of pharmacologyhERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560.
PloS oneFocused ultrasound blood-brain barrier disruption in high-grade gliomas: Scoping review of clinical studies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaSurvival After Newly-Diagnosed High-Grade Glioma Surgery: What Can We Learn From the French National Healthcare Database?
Brain tumor research and treatmentDeep Residual Learning-Based Classification with Identification of Incorrect Predictions and Quantification of Cellularity and Nuclear Morphological Features in Digital Pathological Images of Common Astrocytic Tumors.
CancersGlobal post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022.
Journal of neuro-oncologyPractical Nomograms and Risk Stratification System for Predicting the Overall and Cancer-specific Survival in Patients with Anaplastic Astrocytoma.
World neurosurgeryTRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA-PKcs.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)Development of Predicting Nomograms for Diffuse Astrocytoma and Anaplastic Astrocytoma: A Study Based on the Surveillance, Epidemiology, and End Results Database.
World neurosurgeryGrading of glioma tumors using digital holographic microscopy.
HeliyonModular Hub Genes in DNA Microarray Suggest Potential Signaling Pathway Interconnectivity in Various Glioma Grades.
BiologyVolumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.
Clinical oncology (Royal College of Radiologists (Great Britain))RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Molecular cancerCase report: Diagnostic challenge: a new multiple sclerosis "relapse" leading to the diagnosis of anaplastic astrocytoma.
Frontiers in neurologyTreatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Journal of neuro-oncologyExpression of lncRNAs in glioma: A lighthouse for patients with glioma.
HeliyonBilateral thalamic and brainstem anaplastic astrocytoma: A case report.
MedicineFrom molecular signatures to radiomics: tailoring neurooncological strategies through forecasting of glioma growth.
Neurosurgical focusSurvival Analysis and Correlates with Molecular Epidemiology: 10-Year Retrospective Series of High-Grade Glioma in Pakistan.
Journal of cancer & allied specialtiesFuranocoumarins as Enhancers of Antitumor Potential of Sorafenib and LY294002 toward Human Glioma Cells In Vitro.
International journal of molecular sciencesA phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.
Pediatric blood & cancerZotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
European journal of cancer (Oxford, England : 1990)Lower Plasma Amyloid Beta - 42 Levels Associated With Worse Survival in Patients With Glioma.
In vivo (Athens, Greece)The Role of Bcl-2 and Beclin-1 Complex in "Switching" between Apoptosis and Autophagy in Human Glioma Cells upon LY294002 and Sorafenib Treatment.
CellsNon-invasive diagnosis of brain gliomas by histological type using neuroradiomics in standardized regions of interest: towards digital biopsy.
Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko5-Aminolevulinic acid fluorescence-guided endoscopic surgery for deep-seated intraparenchymal tumors.
British journal of neurosurgeryThe use of sodium MRI in the diagnosis of an anaplastic astrocytoma during immunotherapy: a case report.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryLncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma.
Journal of molecular recognition : JMRBrief report: pediatric high-grade gliomas treated with vinorelbine and valproic acid added to temozolomide.
American journal of cancer researchPrognosis of overall and disease-free survival in patients with grade 3 astrocytomas (anaplastic astrocytoma, WHO 2016).
Zhurnal voprosy neirokhirurgii imeni N. N. BurdenkoConstitutional Mismatch Repair Deficiency (CMMRD) Syndrome: A Case Report of a Patient With Multiple Metachronous Malignancies.
CureusTemozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery.
Naunyn-Schmiedeberg's archives of pharmacologyDiagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Journal of cancer research and therapeuticsIntegrative management of anaplastic astrocytoma through a combination of Ayurveda and conventional care: A case report.
Journal of Ayurveda and integrative medicineAnlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Clinical Medicine Insights. OncologyA Prospective Study of Intensity-modulated Radiation Therapy Using a Standard Radiation Dose for High-grade Glioma.
Cancer diagnosis & prognosisA Case of High-Grade Glioma in an Eloquent Area Treated with Awake Craniotomy in an 85-year-old Patient.
Acta medica OkayamaProstate-Specific Membrane Antigen (PSMA) Expression in The Neovasculature of High Grade Gliomas (Histopathological and Immunohistochemical Study).
Asian Pacific journal of cancer prevention : APJCPDIPG-like MYB-altered diffuse astrocytoma with durable response to intensive chemotherapy.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryRole of cyclin D1 in glial tumors-A retrospective and observational study.
Indian journal of pathology & microbiologyFeasibility of preirradiation temozolomide in cases of high-grade gliomas: Our experience and review of literature.
Journal of cancer research and therapeuticsRecombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.
The Lancet. Child & adolescent healthDemographic variations and time to initiation of adjunct treatment following surgical resection of anaplastic astrocytoma in the United States: a National Cancer Database analysis.
Journal of neuro-oncologyEvaluation of Possible Neobavaisoflavone Chemosensitizing Properties towards Doxorubicin and Etoposide in SW1783 Anaplastic Astrocytoma Cells.
CellsIs Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
CellsProlonged survival in patients with local chronic infection after high-grade glioma treatment: Two case reports.
Frontiers in oncologyIntraoperative Ventricular Opening has No Effect on Complication Development Following BCNU Wafer Implantation for Malignant Glioma.
World neurosurgeryCarbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study.
Annals of translational medicineThe feasibility of MRI texture analysis in distinguishing glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma.
Translational cancer researchPhotodynamic therapy for malignant brain tumors in children and young adolescents.
Frontiers in oncologyAlterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients.
Frontiers in oncologyMalignant transformation in low-grade astrocytoma for long-term monitoring.
Journal of cancer research and therapeuticsNeuro-Physiotherapy Regimen to Enhance the Functional Performance of a Hemiplegic Patient Following Brain Tumor Resection: A Case Report.
CureusPosterior Reversible Encephalopathy Syndrome Developing after Aggressive Posterior Fossa Tumor Surgery.
Asian journal of neurosurgeryRelationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study.
EClinicalMedicineGlobal survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).
Neuro-oncologyEndoscopic resection of thalamic lesions via supracerebellar infratentorial approach: a case series and technical note.
Neurosurgical reviewRole of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma.
Zhurnal voprosy neirokhirurgii imeni N. N. BurdenkoExpression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma.
Asian Pacific journal of cancer prevention : APJCPA rare brainstem anaplastic astrocytoma.
Translational neuroscienceNavigated 3D ultrasound-guided resection of high-grade gliomas: A case series and review.
Surgical neurology internationalTrue anaplastic oligoastrocytoma with dual genotype: illustrative case.
Journal of neurosurgery. Case lessonsRadiosurgery and Stereotactic Brain Radiotherapy with Systemic Therapy in Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic Strategies in Recurrent High-Grade Gliomas.
Journal of personalized medicineCorrigendum: The risk of heart disease-related death among anaplastic astrocytoma patients after chemotherapy: A SEER population-based analysis.
Frontiers in oncologyComprehensive metabolomics study on the pathogenesis of anaplastic astrocytoma via UPLC-Q/TOF-MS.
MedicineDiagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [18F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma.
European journal of nuclear medicine and molecular imagingSynthesis of Aliphatic Polyanhydrides with Controllable and Reproducible Molecular Weight.
PharmaceuticsBrain Gliomas and Ollier Disease: Molecular Findings as Predictive Risk Factors?
CancersRisk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis.
Asian journal of neurosurgeryUsefulness of circulating tumor DNA from cerebrospinal fluid in recurrent high-grade glioma.
Revue neurologiqueInfluence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
Neuro-oncologyA case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism.
Neuropathology : official journal of the Japanese Society of NeuropathologyThe Risk of Heart Disease-Related Death Among Anaplastic Astrocytoma Patients After Chemotherapy: A SEER Population-Based Analysis.
Frontiers in oncologyH3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
World neurosurgeryApplication of 7T MRS to High-Grade Gliomas.
AJNR. American journal of neuroradiologyAnalysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification.
Turkish neurosurgeryGiant Pediatric Supratentorial Tumor: Clinical Feature and Surgical Strategy.
Frontiers in pediatricsGood seizure outcome after focal resection surgery for super-refractory status epilepticus: Report of two cases.
Surgical neurology internationalRemote bifrontal epidural hematoma following hemispheric glioma resection. A rare life-threatening postoperative complication.
Surgical neurology internationalAssessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.
Radiation oncology (London, England)ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors.
CancersUpfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Neuro-oncologyPhase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma.
Cancer research communicationsIschemic Stroke with Multiple Cerebral Artery Stenosis in a Patient with an Anaplastic Astrocytoma during Bevacizumab Treatment: A Case Report.
NMC case report journalCorrelation of Intraoperative 5-ALA-Induced Fluorescence Intensity and Preoperative 11C-Methionine PET Uptake in Glioma Surgery.
Cancers5-Aminolevulinic acid-enhanced fluorescence-guided treatment of high-grade glioma using angled endoscopic blue light visualization: technical case series with preliminary follow-up.
Journal of neurosurgeryBisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics.
Clinical epigeneticsTERT expression increases with tumor grade in a cohort of IDH-mutant gliomas.
American journal of translational researchBevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Journal of neuro-oncologyCase report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma.
Annals of translational medicineFISH analyses for 1p and 19q status on gliomas: Reporting an 8 years' experience from a tertiary care center in the Middle East.
Annals of diagnostic pathologyLarge tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.
BMC neurologyMaximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma.
Scientific reportsBilateral Thalamic Glioma: A Case Report.
CureusPlasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma.
Frontiers in oncologyHormone exposure and its suppressive effect on risk of high-grade gliomas among patients with breast cancer.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaHypermethylation of the Promoter of miR-338-5p Mediates Aberrant Expression of ETS-1 and Is Correlated With Disease Severity Of Astrocytoma Patients.
Frontiers in oncologyFractal analysis of 11C-methionine PET in patients with newly diagnosed glioma.
EJNMMI physicsRelated expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide.
Drug metabolism and personalized therapyCerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients.
BMC cancerGa-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.
NeuroradiologyClinical-pathological study of 28 glial and mixed neuronal-glial tumors diagnosed within the first year of life.
Clinical neuropathologyAggressively recurring cervical intramedullary anaplastic astrocytoma in a pregnant patient.
Surgical neurology internationalCognitive awareness after treatment for high-grade glioma.
Clinical neurology and neurosurgeryIntramedullary Spinal Cord Metastasis Mimicking Astrocytoma: A Rare Case Report.
Brain sciencesAtomic Force Microscope Nanoindentation Analysis of Diffuse Astrocytic Tumor Elasticity: Relation with Tumor Histopathology.
CancersLeptomeningeal dissemination of anaplastic medullary cone astrocytoma: an unexpected findings in a patient with leptomeningeal enhancement and clinical history of multiple myeloma.
PathologicaPrognostic factors and clinical nomogram predicting survival in high-grade glioma.
Journal of cancer research and therapeuticsRadiation Therapy for Grade 3 Gliomas: Correlation of MRI Findings With Prognosis.
CureusSlow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes.
International journal of molecular sciences[Anaplastic astrocytoma and anaplastic oligodendroglioma of the brain: current state of the problem].
Zhurnal voprosy neirokhirurgii imeni N. N. BurdenkoTreatment of anaplastic gliomas: evidences and controversies.
Current opinion in oncologyMultifocal high-grade glioma radiotherapy safety and efficacy.
Radiation oncology (London, England)Intracranial high-grade glioma with malignant progression of spinal intramedullary metastasis: an atypical presentation with review of literature.
British journal of neurosurgeryCerebellar anaplastic astrocytoma in adult patients: 15 consecutive cases from a single institution and literature review.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaRapid Spectroscopic Liquid Biopsy for the Universal Detection of Brain Tumours.
CancersSurgical considerations for maximal safe resection of exophytic brainstem glioma in the pediatric age group.
Surgical neurology internationalA rare, pediatric, fourth-ventricular, anaplastic astrocytoma.
Radiology case reportsMolecularly targeted treatment of recurrent anaplastic astrocytoma - a case report.
Annals of clinical and translational neurologyRemission of Pediatric Diffuse Intrinsic Pontine Glioma: Case Report and Review of the Literature.
Journal of pediatric neurosciencesProton re-irradiation of unresectable recurrent brain gliomas: clinical outcomes and toxicity.
Journal of B.U.ON. : official journal of the Balkan Union of OncologyBiocatalytic Synthesis of Terpene Esters and their Biological Activity in Human Glioma Cells.
Current pharmaceutical biotechnologyLY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Cell and tissue researchNeural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
The Lancet. OncologyThe Dilemma of Multifocality in Insular Tumors: Multicentricity versus Metastasis.
Asian journal of neurosurgerySerum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study.
CancersClinicopathological Profile of Central Nervous System Tumors in a Tertiary Hospital in Southwest Nigeria.
Journal of the West African College of SurgeonsDifferential expression of stem cell markers in proliferating cells in glioma.
Journal of cancer research and clinical oncologyModification of MRI pattern of high-grade glioma pseudoprogression in regorafenib therapy.
Journal of medical imaging and radiation oncologyEstimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience.
The Journal of international medical research[Dynamic11C-methionine PET/CT in differential diagnosis of brain gliomas].
Zhurnal voprosy neirokhirurgii imeni N. N. BurdenkoDifferentiation of Low-Grade Astrocytoma From Anaplastic Astrocytoma Using Radiomics-Based Machine Learning Techniques.
Frontiers in oncologyMolecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas.
Molecular and clinical oncologySMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMolecular investigation of brain tumors progressing during pregnancy or postpartum period: the association between tumor type, their receptors, and the timing of presentation.
Clinical neurology and neurosurgeryImmunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas - institutional experience and review of literature.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryLensoside Aβ as an Adjuvant to the Anti-Glioma Potential of Sorafenib.
CancersInvolvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
International journal of molecular sciencesHypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration.
Neuro-oncology advancesGliomas - An experience based on molecular markers.
Journal of family medicine and primary careBenefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma.
The Lancet. OncologyIntegrated genomic and transcriptomic analysis suggests KRT18 mutation and MTAP are key genetic alterations related to the prognosis between astrocytoma and glioblastoma.
Annals of translational medicineShould CD4 Levels be Monitored in a Patient on Temozolomide?
European journal of case reports in internal medicineCase report and literature review: antenatal diagnosis of a fetal anaplastic astrocytoma.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal ObstetriciansOutcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Japanese journal of clinical oncologyThe role of sex genotype in paediatric CNS tumour incidence and survival.
Child's nervous system : ChNS : official journal of the International Society for Pediatric NeurosurgeryNasal-alar invasive cutaneous aspergillosis in a patient with anaplastic astrocytoma: A case report.
Clinical case reportsUV spectroscopic method for estimation of temozolomide: Application in stability studies in simulated plasma pH, degradation rate kinetics, formulation design, and selection of dissolution media.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopyCorrelation of 4'-[methyl-11C]-thiothymidine PET with Gd-enhanced and FLAIR MRI in patients with newly diagnosed glioma.
EJNMMI researchHigh-Grade Gliomas in Children-A Multi-Institutional Polish Study.
CancersPrognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Neuro-oncologyHigh-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity.
Journal of neuro-oncologyRadiological evaluation of ex novo high grade glioma: velocity of diametric expansion and acceleration time study.
Radiology and oncologyThe Astrogenic Balance in the Aging Brain.
Current neuropharmacology[Phosphorus MR spectroscopy and 18F-FDG PET/CT in the study of energy metabolism of glial tumors].
Zhurnal voprosy neirokhirurgii imeni N. N. BurdenkoDiffusion weighted imaging in high-grade gliomas: A histogram-based analysis of apparent diffusion coefficient profile.
PloS oneCyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis.
Frontiers in oncologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Astrocitoma anaplásico.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Astrocitoma anaplásico e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Ainda não achamos doenças com sintomas parecidos o suficiente.
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
O astrocitoma anaplásico é catalogado clinicamente como um tumor agressivo e infiltrativo do sistema nervoso central. O tratamento visa controlar o crescimento da doença e minimizar os danos neurológicos por meio da conduta médica individualizada.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
8 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Astrocitoma anaplásico. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/astrocitoma-anaplasico
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Astrocitoma anaplásico
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Reposicionamento
- fonte: Drug Repurposing Hub
- Ensaios clínicos
- fonte: ClinicalTrials.gov
